Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial

Journal:
Cancer Cell
Published:
DOI:
10.1016/j.ccell.2025.09.009
Affiliations:
9
Authors:
17
Go to article
Institutions Authors Share
The First Affiliated Hospital, Zhejiang University School of Medicine, China
16.800000
16.800000
 0.99
Zhejiang University (ZJU), China
0.200000
 0.01
Interested in Oncology and Carcinogenesis?